Semaglutide Dosage Calculator
This semaglutide dosage calculator estimates syringe units, concentration, vial yield, and how long a vial will last based on vial size, water volume, and amount per dose
Common semaglutide parameters are pre-selected for faster calculation.
Go to peptide-specific calculator ↓
Result
To have a dose of 1mg pull the syringe to 0
Your vial contains
0.0 dosesConcentration
0.0 mg/mLYour vial will last —
Select Your Specific Peptide
Reconstitution guide
Use our Peptide Calculator below to calculate accurate dosages foradministering peptides using a syringe.
STEP 1
Set your dose
Choose your intended dose in micrograms (mcg): This is the amount of peptide you plan to inject each time.
STEP 2
Enter your peptide strength
Enter the peptide strength in your vial. You can select a common amount, such as 1mg, 5mg, 10mg, or 15mg. If your amount isn’t listed, you can manually type in the exact amount.
STEP 3
Add your water volume
The volume of water you add affects the concentration of the peptide solution. Enter the amount of water in milliliters (mL).
Semaglutide Dosage: What the research says
This information is based on preclinical and clinical research studies. Semaglutide is not FDA-approved for human use. This content is for research and informational purposes only
Common Research Doses
- Low (0.25mg / 250mcg): The universal initiation dosage documented in clinical literature. Research protocols dictate starting at this baseline for a minimum of 4 weeks to assess early gastrointestinal tolerability and initiate metabolic adaptation.¹
- Mid (0.5mg to 1.0mg): The established maintenance dosage for glycemic control models. In experimental setups, reaching and sustaining this threshold correlates with significant shifts in insulin secretion, delayed gastric emptying, and steady reductions in HbA1c.²
- High (2.5mg): The target therapeutic threshold evaluated in long-term weight management and cardiovascular outcome trials. Studies demonstrate maximum systemic fat mass clearance at 2.4mg, though researchers uniformly mandate a strict, multi-month step-wise titration schedule to mitigate adverse autonomic and gastrointestinal events.¹
Frequency of Administration
In experimental protocols, semaglutide is administered once weekly. Due to a structural modification that promotes strong albumin binding and protects against DPP-4 degradation, its systemic half-life extends to approximately 7 days, providing a stable pharmacokinetic profile through weekly intervals.¹
Route of Administration
The standard and most thoroughly documented route in clinical literature is Subcutaneous (SubQ) injection, typically via the abdomen. Subcutaneous delivery ensures steady systemic absorption and distribution to GLP-1 receptors located in the pancreas, the gastrointestinal tract, and the central nervous system.²
Study Duration
Semaglutide research generally follows longitudinal timelines to safely escalate the dosage and track extended metabolic remodeling:
- Acute / Titration Phase: 16 to 20 weeks to safely titrate the compound from the 0.25mg baseline up to the 2.4mg target maintenance dose.
- Longitudinal / Efficacy Phase: 68+ weeks. Extensive Phase 3 trials (such as the STEP 1 trial) administered semaglutide continuously for 68 weeks to observe sustained weight loss plateaus, cardiometabolic safety, and overall systemic tolerance.¹
Evidence Limitations
While commercial pharmaceutical formulations of semaglutide have received FDA approval for the management of type 2 diabetes and obesity, the research-grade peptide data provided here is strictly for educational context. All Honest Peptide compounds are restricted strictly to Research Use Only (RUO) and are not for human consumption or therapeutic use. For catalog navigation and laboratory procurement, Semaglutide is designated within our catalog under the compliant nomenclature GLP-1 S.
Scientific References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019;45(5):409-418. https://pubmed.ncbi.nlm.nih.gov/30615985/
Shop peptides
